JeanRene Fourtou - Sanofi ADR Independent Director
| SNY Stock | USD 49.13 0.23 0.47% |
Director
Mr. JeanRene Fourtou was Independent Director of Sanofi SA since August 2004 and he is also Member of the Remuneration and Chairman of Nominating and Governance Committees and Member of the Strategy Committee of the Company. He is also Chairman of the Supervisory Board of Vivendi and Member of the Supervisory Board of Maroc Telecom. He served as Director and Member of the Remunerations Committee of Nestle until 2012. Until 2010 he served as Director of NBC Universal Inc among others. Mr. Fourtou previously held various positions at the Bossard group from 1963 to 1986 including Chairman and Chief Executive Officer . From 1986 to 1999 he was Chairman and Chief Executive Officer of RhonePoulenc between 1999 and 2004 he was Vice Chairman of the Management Board Vice Chairman of the Supervisory Board and Member of the Strategy Committee of Aventis and from 2002 to 2005 he was Chairman and Chief Executive Officer of Vivendi. He also held various mandates including Vice President then Member of the Supervisory Board of Axa from 1990 to 2009. Mr. Fourtou graduated from the Ecole Polytechnique de Paris in 1963. since 2004.
| Age | 75 |
| Tenure | 20 years |
| Phone | 33 1 53 77 40 00 |
| Web | https://www.sanofi.com |
Sanofi ADR Management Efficiency
The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0727 %, implying that it generated $0.0727 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Gregory Garland | Amgen Inc | 60 | |
| Anita Hauser | Roche Holding Ltd | 49 | |
| Greg Garland | Amgen Inc | 56 | |
| Mary Coe | Merck Company | 54 | |
| Thomas Cech | Merck Company | 72 | |
| Frank Biondi | Amgen Inc | 70 | |
| Paul Bulcke | Roche Holding Ltd | 64 | |
| Edward Liddy | AbbVie Inc | 75 | |
| Togo West | Bristol Myers Squibb | 72 | |
| Genevieve Berger | AstraZeneca PLC ADR | 64 | |
| Weiying Wang | AstraZeneca PLC ADR | N/A | |
| Mark Weinberger | Johnson Johnson | 59 | |
| Bridgette Heller | Novartis AG ADR | 59 | |
| Marcus Wallenberg | AstraZeneca PLC ADR | 63 | |
| Manvinder Banga | GlaxoSmithKline PLC ADR | 62 | |
| Gayle Wilson | Gilead Sciences | 75 | |
| Stacey Cartwright | GlaxoSmithKline PLC ADR | 51 | |
| Christoph Franz | Roche Holding Ltd | 58 | |
| Dinesh Paliwal | Bristol Myers Squibb | 63 | |
| Peter Wendell | Merck Company | 70 | |
| Ian Davis | Johnson Johnson | 70 | |
Management Performance
| Return On Equity | 0.0727 | ||||
| Return On Asset | 0.0454 |
Sanofi ADR Leadership Team
Elected by the shareholders, the Sanofi ADR's board of directors comprises two types of representatives: Sanofi ADR inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi ADR's management team and ensure that shareholders' interests are well served. Sanofi ADR's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi ADR's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee | ||
| Emmanuel Babeau, Independent Director | ||
| Roy Papatheodorou, Executive Counsel | ||
| Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team | ||
| Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee | ||
| Dieter Weinand, Executive Vice President Member of the Executive Board | ||
| Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team | ||
| Eva SchaeferJansen, Head Relations | ||
| Fabienne Lecorvaisier, Director | ||
| George Grofik, Vice President of Investor Relations | ||
| Karen Linehan, Executive VP of Legal Affairs and General Counsel | ||
| Klaus Pohle, Independent Director | ||
| John Reed, President - Global Research & Development, Member of the Executive Committee | ||
| Bernard Charles, Independent Director | ||
| Natalie Bickford, Executive Officer | ||
| FranoisXavier Roger, Chief Officer | ||
| Melanie Lee, Independent Director | ||
| Madeleine Roach, Executive Operations | ||
| Pierre Chancel, Senior Marketing | ||
| Christophe Babule, Director | ||
| Bonnie Bassler, Director | ||
| Thomas Suedhof, Independent Director | ||
| Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee | ||
| Laurent Attal, Director | ||
| JeanRene Fourtou, Independent Director | ||
| JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee | ||
| Josephine Fubara, Chief Care | ||
| Christian Mulliez, Director | ||
| Robert Castaigne, Independent Director | ||
| Laurent Gilhodes, Principal Accounting | ||
| Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team | ||
| Uwe Bicker, Independent Director | ||
| Josep Catlla, Head Communications | ||
| Claudie Haignere, Independent Director | ||
| Olivier Brandicourt, CEO, Director and Member of Strategy Committee | ||
| Paul Hudson, CEO Director | ||
| Bruno Mnard, Chief officer | ||
| Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team | ||
| Dante Beccaria, Global VP | ||
| Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee | ||
| William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee | ||
| Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team | ||
| David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe | ||
| Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team | ||
| Diane Souza, Independent Director | ||
| Carole Piwnica, Independent Director | ||
| Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team | ||
| Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee | ||
| Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team | ||
| Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team | ||
| DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee | ||
| Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team | ||
| Igor Landau, Director | ||
| Patrick Kron, Independent Director | ||
| Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee | ||
| Gerard Kemmel, Independent Director | ||
| SuetFern Lee, Independent Director | ||
| Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team | ||
| David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team | ||
| Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee | ||
| Suet Lee, Independent Director |
Sanofi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanofi ADR a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0727 | ||||
| Return On Asset | 0.0454 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 71.37 B | ||||
| Shares Outstanding | 2.5 B | ||||
| Shares Owned By Institutions | 9.99 % | ||||
| Number Of Shares Shorted | 3.24 M | ||||
| Price To Earning | 7.78 X | ||||
| Price To Book | 1.44 X |
Currently Active Assets on Macroaxis
When determining whether Sanofi ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanofi ADR's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanofi Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanofi Adr Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Sanofi Stock analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.